We Can Medicines Co (ROCO:6929) Other Current Receivables: NT$58 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6929 We Can Medicines Co Ltd ROCO:6929
47 GF Score
Price NT$21.50
GF Value NT$39.14
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is We Can Medicines Co Other Current Receivables?

We Can Medicines Co ROCO:6929 -6.52% 47 Other Current Receivables is NT$58 Mil as of Mar. 2026. GuruFocus rates ROCO:6929 with a GF Score™ of 47/100 and a GF Value™ of NT$39.14 (Possible Value Trap). The stock has 3 warning signs investors should review.

We Can Medicines Co's Other Current Receivables for the quarter that ended in Mar. 2026 was NT$58 Mil.

We Can Medicines Co's quarterly Other Current Receivables increased from Sep. 2025 (NT$38.16 Mil) to Dec. 2025 (NT$41.23 Mil) and increased from Dec. 2025 (NT$41.23 Mil) to Mar. 2026 (NT$58.36 Mil).

We Can Medicines Co's annual Other Current Receivables declined from Dec. 2023 (NT$40.24 Mil) to Dec. 2024 (NT$39.18 Mil) but then increased from Dec. 2024 (NT$39.18 Mil) to Dec. 2025 (NT$41.23 Mil).

We Can Medicines Co Other Current Receivables Related Terms

We Can Medicines Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for We Can Medicines Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

We Can Medicines Co Other Current Receivables Chart

We Can Medicines Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 26.40 28.11 40.24 39.18 41.23

We Can Medicines Co Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.01 38.01 38.16 41.23 58.36
ROCO:6929
47GF Score
We Can Medicines Co Ltd ROCO:6929
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

We Can Medicines Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$58 Mil mean?
We Can Medicines Co (ROCO:6929) has a Other Current Receivables of NT$58 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on We Can Medicines Co and its competitors.
Is We Can Medicines Co's Other Current Receivables too high?
We Can Medicines Co's current Other Current Receivables is NT$58 Mil. Overall, We Can Medicines Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's Other Current Receivables compare to KHC and GIS?
We Can Medicines Co's Other Current Receivables of NT$58 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Consumer Packaged Goods company?
A good Other Current Receivables depends on the Consumer Packaged Goods industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on We Can Medicines Co and its competitors. We Can Medicines Co's current Other Current Receivables is NT$58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$39.14, compared to a current price of NT$21.50 — trading 45.1% below its estimated fair value. The current Other Current Receivables is NT$58 Mil. We Can Medicines Co's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current Other Current Receivables is NT$58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?

Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued. The current stock price of NT$21.50 is trading 45.1% below its estimated GF Value™ of NT$39.14. GuruFocus considers We Can Medicines Co to be Possible Value Trap.

Key valuation signals for ROCO:6929:

  • Other Current Receivables: NT$58 Mil
  • GF Value™: NT$39.14 vs. price of NT$21.50 (45.1% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

We Can Medicines Co Business Description

Address Section 4, Taiwan Avenue, 20th Floor-1, No. 925, Xitun District, Taichung, TWN
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
47GF Score

Get the complete analysis for ROCO:6929

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.50
Price
NT$39.14
GF Value